Parthanatos and its associated components: Promising therapeutic targets for cancer

• Published in: Pharmacological research Vol. 163; p. 105299
• Main Authors: Zhou, Yunxiang, Liu, Lihong, Tao, Sifeng, Yao, Yihan, Wang, Yali, Wei, Qichun, Shao, Anwen, Deng, Yongchuan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.01.2021
• Subjects: AIF; ARH3; MIF; PARG; PARP1; Parthanatos; Regulated necrosis; Therapeutic target; Tumorigenesis; PAR; TMZ; ARH3; PARG; CHK; PTEN; HR; CDK; Therapeutic target; HIF-1; DSB; Tumorigenesis; E-cad; TNBC; AIF; p-ERK; SSB; TRAIL; MLKL; PARP1; RIPK3; VEGF; MIF; EMT; BER; bFGF; Parthanatos; NAD; Regulated necrosis; ROS; TJs; NK; MNNG; PARylation

[Display omitted] Parthanatos is a PARP1-dependent, caspase-independent, cell-death pathway that is distinct from apoptosis, necrosis, or other known forms of cell death. Parthanatos is a multistep pathway that plays a pivotal role in tumorigenesis. There are many molecules in the parthanatos cascad...